A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD (-) ACUTE MYELOID LEUKEMIA (QUANTUM-WT) (QUIZARTINIB OR PLACEBO PLUS CHEMOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD (-) AML)